Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02051218). This is a study registration, not published results. Lead sponsor: Swiss Cancer Institute. Recruitment status: TERMINATED. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1380 participants (ACTUAL). Conditions: Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases. Interventions: DRUG: Denosumab (reduced dosing); DRUG: Denosumab (standard dosing). Primary outcome measures: Time to first on-trial symptomatic skeletal event (SSE; Clinically significant pathological fracture, radiation therapy to bone, surgery to bone or spinal cord compression). , at the latest 5 years after randomization.. Brief summary: The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if administered only every 12 weeks as compared to every 4 weeks.